Regulatory risk CRI Genetics has faced regulatory scrutiny for deceptive practices with a past settlement (Nov 2023). Highlightes a need for compliance enhancements, transparent marketing, and third-party audits when engaging prospects in regulated markets.

Consumer biotech reach Small to mid-sized consumer genetics focus with diverse health reports launched since 2020 indicates opportunity to upsell premium health and wellness insights, especially to customers seeking personalized nutrition and lifestyle recommendations.

Strategic partnerships Recent advisory hire and visible industry involvement suggest open avenues for channel partnerships, co-branding with health platforms, and integration into wellness ecosystems to expand distribution and credibility.

Product expansion Historically launched niche health reports (stress reactivity, misophonia, vitamin A) and consumer DNA insights present a pathway to broaden offerings into clinically relevant panels for primary care or specialty clinics.

SME growth potential Company size and revenue positioning (low-to-mid seven figures) indicate opportunities for scalable B2B sales, white-label solutions, or OEM partnerships with mid-market genetic testing platforms seeking to expand their catalog.